Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announces the launch of the Viz TM Vascular Suite , a AI-powered software enabling vascular care teams to automatically detect and prioritize care for suspected pulmonary embolism, right heart overload, aortic dissection and abdominal aortic aneurysm (AAA). 1 Viz.ai has submitted a new 510(k) application to the US Food and Drug Administration (FDA) for the AAA algorithm.

“Recognizing the symptoms of serious vascular disease, such as aortic dissections, is extremely important because any delay in treatment can directly impact patient outcomes,” says Philip Batista, MD, Associate Program Director, Residency of Vascular and Endovascular Surgery, Cooper. “When Viz identifies an abnormal CT scan, it quickly notifies specialists regardless of location, ensuring seamless communication via a mobile app. We have been using Viz software for several months and have seen improvements in patient care across the board. our establishment.

The Viz Vascular Suite uses artificial intelligence to automatically analyze an array of imaging modalities including computed tomography and electrocardiogram for suspected vascular disease. If a suspected pathology is found, the app automatically alerts and displays high-resolution scans on caregivers' mobile devices. Clinicians can use the Viz Vascular Suite to remotely coordinate vascular pathology care within the hospital system's hub-and-spoke network and enable synchronous, HIPAA-compliant communication between specialists. The platform is powered by AI for immediate team activation and facilitates informed and effective treatment decisions.

"We set out to build a solution where every patient with life-threatening diseases can benefit from AI-powered care coordination with real-time mobile screening and communication. The Viz Vascular Suite will bring the benefits of a smart coordination of care to even more patients and will help clinical teams achieve better clinical outcomes,” said Chris Mansi, CEO of Viz.ai. "Reviews from our early adopters have been very positive, and we look forward to expanding access to this solution to our customer base of over 1,300 hospitals."

About Viz.ai, Inc.

Viz.ai is pioneering the use of AI algorithms and machine learning to accelerate diagnosis and care, covering more than 200 million people in more than 1,300 hospitals and healthcare systems in the United States and in Europe. Powered by AI, the Viz platform is an intelligent care coordination solution that helps diagnose more patients with a specific disease, inform critical point-of-care decisions, optimize care pathways and help improve results. Powered by clinical data, the Viz platform delivers significant value to patients, caregivers, and pharmaceutical and medical device companies. For more information, visit viz.ai.

1 Suspected abdominal aortic aneurysm is pending 510(k). Not available for sale.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.

Contacts
Media Contact:
Erich Sandoval
erich.sandoval@finnpartners.com
1-917-497-2867

 

Source:businesswire.com

Report Abuse